about
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicinesBiologic therapies: what and when?Different methods of balancing covariates leading to different effect estimates in the presence of effect modificationA Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients
P2860
description
im August 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 24 August 2004
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2004
@uk
name
BSR Biologics Registry
@en
BSR Biologics Registry
@nl
type
label
BSR Biologics Registry
@en
BSR Biologics Registry
@nl
prefLabel
BSR Biologics Registry
@en
BSR Biologics Registry
@nl
P2093
P356
P1433
P1476
BSR Biologics Registry
@en
P2093
D G I Scott
I Griffiths
P304
P356
10.1093/RHEUMATOLOGY/KEH356
P577
2004-08-24T00:00:00Z